Publisher’s Note Recurrent Pericarditis: A Toolkit for Health Care Professionals is published by: Ascend Media 401 SW Ward Road, Suite 210, Lee’s Summit, MO 64081 © 2026 American Heart Association, Inc., a 501(c)(3) not-for-profit. All rights reserved. Unauthorized use prohibited. All references and data are as of February 2026. Disclaimer: This toolkit incorporates therapeutic information from the 2025 European Society of Cardiology Guidelines for the management of myocarditis and pericarditis, which currently constitute the most comprehensive, evidence-based recommendations available in the absence of an American Heart Association pericarditis guideline. However, drug approvals and market availability differ across jurisdictions. While certain interleukin-1 (IL-1) inhibitors — such as anakinra and canakinumab — are authorized in both the United States and the European Union, they are not approved specifically for recurrent pericarditis. Other agents, like rilonacept (approved in the U.S.) or goflikicept (approved in Russia), may be available only in select regions. Clinicians should adhere to best practices based on current evidence and the therapeutics available in their region. The inclusion or mention of any pharmaceutical product does not constitute Heart Association endorsement.
RkJQdWJsaXNoZXIy MjI2NjI=